Dermata Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
DRMA$0.71-7.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
| For the year endedDecember 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating expenses: | ||
| Research and development | $4,069,766 | $5,651,041 |
| General and administrative | 3,972,140 | 4,023,445 |
| Total operating expenses | 8,041,906 | 9,674,486 |
| Loss from operations | (8,041,906) | (9,674,486) |
| Other income and expenses: | ||
| Interest income, net | (247,216) | (63,573) |
| Net loss | $(7,794,690) | $(9,610,913) |
| Net loss per share of common stock, basic and diluted | $(2.67) | $(13.92) |
| Weighted-average basic and diluted common shares | 2,924,398 | 690,666 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.